CompletedPhase 1Results posted

Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia Taking Stable Donepezil Treatment (MK-1167-007)

A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Assess the Safety, Tolerability, and Pharmacokinetics of MK-1167 Administered to Patients With Alzheimer's Disease Receiving Stable Donepezil Treatment

Lead sponsor

Merck Sharp & Dohme LLC

Assets

Donepezil / MK-1167

Listed sites

Recruiting sites

Enrollment

actual

Study population

Alzheimer’s disease

Key I/E criteria

•Alzheimer's disease•Study partner/caregiver required

Primary endpoints

•Adverse Event (AE)•Number of Participants Who Discontinued Study Treatment Due to an AE

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

Org study ID1167-007

Secondary IDMK-1167-007MSD

NCT IDNCT06285240

Timeline

Milestones

Study first posted2024-02-29actual

Study start2024-03-28actual

Primary completion2024-09-23actual

Study completion2024-09-23actual

Last update posted2025-10-14actual

Results first posted2025-10-14actual

Assets

Drug assets

Donepezil MK-1167

Study populations

Who this study enrolls

Alzheimer’s disease

Eligibility

Who can enroll

Minimum age50 Years

Maximum age90 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Reports a history of cognitive and functional decline with gradual onset and slow progression for at least 1 year before Screening, that is either corroborated by an informant who knows the subject well or is documented in medical records

•Meets the criteria for a diagnosis of probable Alzheimer's disease (AD) based on the National Institute of Neurological and Communicative Disorders - Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria for probable AD

•Is receiving donepezil 10 mg daily for symptomatic treatment of cognitive impairment associated with AD. The dose level must be stable for at least 2 months prior to Screening. If receiving donepezil via a transdermal system (ie, patch), it should be a 10-mg/day dose and should switch prescription to a 10-mg oral daily dose, before enrollment

•Has a reliable and competent trial partner/caregiver who has a close relationship with the participant, has face-to-face contact at least 3 days a week for a minimum of 6 waking hours a week, and is willing to accompany the participant, if desired, to study visits

Exclusion criteria

•History of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases that are not under medical control over the past 2 months.

•Has evidence of a clinically relevant or unstable psychiatric disorder, based on DSM-5 criteria, or has a history of clinically significant psychiatric disorder in the last 5 years. Generalized anxiety disorder, and/or insomnia under good control for ≥ 2 months on stable medical therapy may not be exclusionary.

•History of cancer (malignancy). Participants with adequately treated disease deemed as "cured," or who, in the opinion of the study investigator, are highly unlikely to sustain a recurrence for the duration of the study, may be enrolled at the discretion of the investigator and Sponsor.

•History of significant multiple and/or severe allergies (eg, food, drug, latex allergy), or has had an anaphylactic reaction or significant intolerability (ie, systemic allergic reaction) to prescription or nonprescription drugs or food.

•Had a major surgery and/or donated or lost 1 unit of blood (approximately 500 mL) within 4 weeks prior to the prestudy (screening) visit.

•Unable to refrain from or anticipates the use of any medication, including prescription and nonprescription drugs or herbal remedies beginning approximately 2 weeks (or 5 half-lives) prior to administration of the initial dose of study intervention, throughout the study, until the poststudy visit. There may be certain protocol-specified medications that are permitted.

•The participant is a smoker and/or has used nicotine or nicotine-containing products (eg, nicotine patch and electronic cigarette) within 3 months of screening.

•Consumes greater than 3 servings of alcoholic beverages per day. Participants who consume 4 servings of alcoholic beverages per day may be enrolled at the discretion of the investigator.

•The participant is a regular user of cannabis, any illicit drugs or has a history of drug (including alcohol) abuse within approximately 2 years.

Endpoints (52)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Safety / tolerability / PK

Other (unclassified)

Safety / tolerability / PK

28 endpoints

Primary/protocol endpoint

Number of Participants Who Experienced an Adverse Event (AE)

Time frame:Up to approximately 7 weeks

event count, event

Primary/registry result

Number of Participants Who Experienced an Adverse Event (AE)

Time frame:Up to approximately 7 weeks

event count, event

Posted result

Group	Value (count_of_participants), Participants	Reported bounds
Panel A: MK-1167 6mg QD + Donepezil 10mg QDn=12 Participants	3	-
Panel A: MK-1167 3mg QD + Donepezil 10mg QDn=12 Participants	5	-
Panel A: Placebo to MK-1167 + Donepezil 10mg QDn=4 Participants	2	-
Panel B: MK-1167 6mg QD+ Donepezil 10mg QDn=9 Participants	6	-
Panel B: Placebo to MK-1167 + Donepezil 10mg QDn=3 Participants	0	-

Secondary/protocol endpoint

Panel A: Area Under the Plasma Concentration-Time Curve From 0 to 24 Hours (AUC0-24) After Administration of 6mg of MK-1167

Time frame:Day 1: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose

concentration, descriptive

Secondary/protocol endpoint

Panel A: AUC0-24 After Administration of 3mg of MK-1167

Time frame:Days 8, 21: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose

concentration, descriptive

Secondary/protocol endpoint

Panel A: Maximum Plasma Concentration (Cmax) After Administration of 6mg of MK-1167

Time frame:Day 1: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose

concentration, descriptive

Secondary/protocol endpoint

Panel A: Cmax After Administration of 3mg of MK-1167

Time frame:Days 8, 21: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose

concentration, descriptive

Secondary/protocol endpoint

Panel B: Cmax After Administration of 6mg of MK-1167

Time frame:Days 1, 23, 31: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose

concentration, descriptive

Secondary/protocol endpoint

Panel A: Plasma Concentration at 24 Hours (C24) After Administration of 6mg of MK-1167

Time frame:Day 1: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose

concentration, descriptive

Secondary/protocol endpoint

Panel A: Time to Maximum Plasma Concentration (Tmax) After Administration of 6mg of MK-1167

Time frame:Day 1: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose

time to event, event

Secondary/protocol endpoint

Panel A: Tmax After Administration of 3mg of MK-1167

Time frame:Days 8, 21: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose

time to event, event

Secondary/protocol endpoint

Panel B: Tmax After Administration of 6mg of MK-1167

Time frame:Days 1, 23, 31: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose

time to event, event

Secondary/registry result

Panel A: Area Under the Plasma Concentration-Time Curve From 0 to 24 Hours (AUC0-24) After Administration of 6mg of MK-1167

Time frame:Day 1: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose

concentration, descriptive

Posted result

Group	Value (geometric_mean), μM*hour	Reported bounds
Panel A: MK-1167 6mg QD + Donepezil 10mg QDn=10 Participants	2.17	-1.22 - 3.84

Secondary/protocol endpoint

Panel A: Apparent Terminal Half-Life (t1/2) After Administration of 3mg of MK-1167

Time frame:Day 21: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 120, 240, 360 and 480 hours postdose

concentration, descriptive

Secondary/registry result

Panel A: AUC0-24 After Administration of 3mg of MK-1167

Time frame:Days 8, 21: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose

concentration, descriptive

Posted result

Group	Value (geometric_mean), μM*hour	Reported bounds
Panel A: MK-1167 3mg QD + Donepezil 10mg QDDay 8n=12 Participants	8.70	-4.95 - 15.3
Day 21n=10 Participants	8.08	-4.56 - 14.3

Secondary/protocol endpoint

Panel B: t1/2 After Administration of 6mg of MK-1167

Time frame:Day 31: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 120, 240, 360 and 480 hours postdose

concentration, descriptive

Secondary/registry result

Panel A: Maximum Plasma Concentration (Cmax) After Administration of 6mg of MK-1167

Time frame:Day 1: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose

concentration, descriptive

Posted result

Group	Value (geometric_mean), μmol/Liter	Reported bounds
Panel A: MK-1167 6mg QD + Donepezil 10mg QDn=10 Participants	0.129	-0.0731 - 0.228

Secondary/registry result

Panel A: Cmax After Administration of 3mg of MK-1167

Time frame:Days 8, 21: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose

concentration, descriptive

Posted result

Group	Value (geometric_mean), μmol/Liter	Reported bounds
Panel A: MK-1167 3mg QD + Donepezil 10mg QDDay 8n=12 Participants	0.434	-0.247 - 0.761
Day 21n=10 Participants	0.413	-0.234 - 0.729

Secondary/registry result

Panel B: Cmax After Administration of 6mg of MK-1167

Time frame:Days 1, 23, 31: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose

concentration, descriptive

Posted result

Group	Value (geometric_mean), μmol/Liter	Reported bounds
Panel B: MK-1167 6mg QD + Donepezil 10mg QDDay 1n=9 Participants	0.145	-0.121 - 0.174
Day 23n=8 Participants	1.11	-0.919 - 1.35
Day 31n=8 Participants	1.14	-0.941 - 1.38

Secondary/registry result

Panel A: Plasma Concentration at 24 Hours (C24) After Administration of 6mg of MK-1167

Time frame:Day 1: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose

concentration, descriptive

Posted result

Group	Value (geometric_mean), μmol/Liter	Reported bounds
Panel A: MK-1167 6mg QD + Donepezil 10mg QDn=10 Participants	0.0902	-0.0500 - 0.163

Secondary/protocol endpoint

Panel B: Day 23 to Day 1 Accumulation Ratio of Cmax After Administration of 6mg of MK-1167

Time frame:Days 1, 23: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose

concentration, descriptive

Secondary/protocol endpoint

Panel B: Day 31 to Day 1 Accumulation Ratio of Cmax After Administration of 6mg of MK-1167

Time frame:Days 1, 31: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose

concentration, descriptive

Secondary/registry result

Panel A: Time to Maximum Plasma Concentration (Tmax) After Administration of 6mg of MK-1167

Time frame:Day 1: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose

time to event, event

Posted result

Group	Value (median), hours	Reported bounds
Panel A: MK-1167 6mg QD + Donepezil 10mg QDn=10 Participants	1.54	-0.50 - 8.00

Secondary/registry result

Panel A: Tmax After Administration of 3mg of MK-1167

Time frame:Days 8, 21: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose

time to event, event

Posted result

Group	Value (median), hours	Reported bounds
Panel A: MK-1167 3mg QD + Donepezil 10mg QDDay 8n=12 Participants	6.00	-0.00 - 23.97
Day 21n=10 Participants	4.01	-1.22 - 11.92

Secondary/registry result

Panel B: Tmax After Administration of 6mg of MK-1167

Time frame:Days 1, 23, 31: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose

time to event, event

Posted result

Group	Value (median), hours	Reported bounds
Panel B: MK-1167 6mg QD + Donepezil 10mg QDDay 1n=9 Participants	1.08	-0.48 - 5.78
Day 23n=8 Participants	4.03	-0.58 - 11.92
Day 31n=8 Participants	2.97	-0.42 - 11.90

Secondary/registry result

Panel A: Apparent Terminal Half-Life (t1/2) After Administration of 3mg of MK-1167

Time frame:Day 21: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 120, 240, 360 and 480 hours postdose

concentration, descriptive

Posted result

Group	Value (geometric_mean), hours	Geometric coefficient of variation
Panel A: MK-1167 3 mg QD + Donepezil 10mg QDn=10 Participants	194	48.2

Secondary/registry result

Panel B: t1/2 After Administration of 6mg of MK-1167

Time frame:Day 31: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 120, 240, 360 and 480 hours postdose

concentration, descriptive

Posted result

Group	Value (geometric_mean), hour	Geometric coefficient of variation
Panel B: MK-1167 6mg QD + Donepezil 10mg QDn=8 Participants	193	40.4

Secondary/registry result

Panel B: Day 23 to Day 1 Accumulation Ratio of Cmax After Administration of 6mg of MK-1167

Time frame:Days 1, 23: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose

concentration, descriptive

Posted result

Group	Value (geometric_mean), Ratio	Reported bounds
Panel B: MK-1167 6mg QD + Donepezil 10mg QDn=8 Participants	7.69	-6.46 - 9.16

Secondary/registry result

Panel B: Day 31 to Day 1 Accumulation Ratio of Cmax After Administration of 6mg of MK-1167

Time frame:Days 1, 31: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose

concentration, descriptive

Posted result

Group	Value (geometric_mean), Ratio	Reported bounds
Panel B: MK-1167 6mg QD + Donepezil 10mg QDn=8 Participants	7.88	-6.62 - 9.38

Other (unclassified)

24 endpoints

Primary/protocol endpoint/low confidence

Number of Participants Who Discontinued Study Treatment Due to an AE

Time frame:Up to approximately 4 weeks

event count, event

Primary/registry result/low confidence

Number of Participants Who Discontinued Study Treatment Due to an AE

Time frame:Up to approximately 4 weeks

event count, event

Posted result

Group	Value (count_of_participants), Participants	Reported bounds
Panel A: MK-1167 6mg QD + Donepezil 10mg QDn=12 Participants	0	-
Panel A: MK-1167 3mg QD + Donepezil 10mg QDn=12 Participants	0	-
Panel A: Placebo to MK-1167 + Donepezil 10mg QDn=4 Participants	0	-
Panel B: MK-1167 6mg QD + Donepezil 10mg QDn=9 Participants	1	-
Panel B: Placebo to MK-1167 + Donepezil 10mg QDn=3 Participants	0	-

Secondary/protocol endpoint/low confidence

Panel B: AUC0-24 After Administration of 6mg of MK-1167

Time frame:Days 1, 23, 31: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose

concentration, descriptive

Secondary/protocol endpoint/low confidence

Panel A: C24 After Administration of 3mg of MK-1167

Time frame:Days 8, 21: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose

concentration, descriptive

Secondary/protocol endpoint/low confidence

Panel B: C24 After Administration of 6mg of MK-1167

Time frame:Days 1, 23, 31: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose

concentration, descriptive

Secondary/protocol endpoint/low confidence

Panel A: Apparent Clearance (CL/F) After Administration of 3mg of MK-1167

Time frame:Day 21: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 120, 240, 360 and 480 hours postdose

ratio, descriptive

Secondary/protocol endpoint/low confidence

Panel B: CL/F After Administration of 6mg of MK-1167

Time frame:Day 31: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 120, 240, 360 and 480 hours postdose

ratio, descriptive

Secondary/registry result/low confidence

Panel B: AUC0-24 After Administration of 6mg of MK-1167

Time frame:Days 1, 23, 31: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose

concentration, descriptive

Posted result

Group	Value (geometric_mean), μM*hour	Reported bounds
Panel B: MK-1167 6mg QD + Donepezil 10mg QDDay 1n=9 Participants	2.48	-2.04 - 3.01
Day 23n=8 Participants	22.2	-18.1 - 27.1
Day 31n=8 Participants	22.9	-18.8 - 28.0

Secondary/protocol endpoint/low confidence

Panel A: Apparent Volume of Distribution (Vz/F) After Administration of 3mg of MK-1167

Time frame:Day 21: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 120, 240, 360 and 480 hours postdose

ratio, descriptive

Secondary/protocol endpoint/low confidence

Panel B: Vz/F After Administration of 6mg of MK-1167

Time frame:Day 31: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 120, 240, 360 and 480 hours postdose

ratio, descriptive

Secondary/protocol endpoint/low confidence

Panel B: Day 23 to Day 1 Accumulation Ratio of AUC0-24 After Administration of 6mg of MK-1167

Time frame:Days 1, 23: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose

concentration, descriptive

Secondary/protocol endpoint/low confidence

Panel B: Day 31 to Day 1 Accumulation Ratio of AUC0-24 After Administration of 6mg of MK-1167

Time frame:Days 1, 31: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose

concentration, descriptive

Secondary/registry result/low confidence

Panel A: C24 After Administration of 3mg of MK-1167

Time frame:Days 8, 21: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose

concentration, descriptive

Posted result

Group	Value (geometric_mean), μmol/Liter	Reported bounds
Panel A: MK-1167 3mg QD + Donepezil 10mg QDDay 8n=12 Participants	0.362	-0.203 - 0.647
Day 21n=10 Participants	0.313	-0.174 - 0.565

Secondary/registry result/low confidence

Panel B: C24 After Administration of 6mg of MK-1167

Time frame:Days 1, 23, 31: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose

concentration, descriptive

Posted result

Group	Value (geometric_mean), μmol/Liter	Reported bounds
Panel B: MK-1167 6mg QD + Donepezil 10mg QDDay 1n=9 Participants	0.0917	-0.0731 - 0.115
Day 23n=8 Participants	0.729	-0.576 - 0.922
Day 31n=8 Participants	0.875	-0.691 - 1.11

Secondary/protocol endpoint/low confidence

Panel B: Day 23 to Day 1 Accumulation Ratio of C24 After Administration of 6mg of MK-1167

Time frame:Days 1, 23: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose

concentration, descriptive

Secondary/protocol endpoint/low confidence

Panel B: Day 31 to Day 1 Accumulation Ratio of C24 After Administration of 6mg of MK-1167

Time frame:Days 1, 31: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose

concentration, descriptive

Secondary/registry result/low confidence

Panel A: Apparent Clearance (CL/F) After Administration of 3mg of MK-1167

Time frame:Day 21: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 120, 240, 360 and 480 hours postdose

ratio, descriptive

Posted result

Group	Value (geometric_mean), Liter/hour	Geometric coefficient of variation
Panel A: MK-1167 3mg QD + Donepezil 10mg QDn=10 Participants	0.879	166.9

Secondary/registry result/low confidence

Panel B: CL/F After Administration of 6mg of MK-1167

Time frame:Day 31: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 120, 240, 360 and 480 hours postdose

ratio, descriptive

Posted result

Group	Value (geometric_mean), Liter/hour	Geometric coefficient of variation
Panel B: MK-1167 6mg QD + Donepezil 10mg QDn=8 Participants	0.606	32.3

Secondary/registry result/low confidence

Panel A: Apparent Volume of Distribution (Vz/F) After Administration of 3mg of MK-1167

Time frame:Day 21: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 120, 240, 360 and 480 hours postdose

ratio, descriptive

Posted result

Group	Value (geometric_mean), Liter	Geometric coefficient of variation
Panel A: MK-1167 3mg QD + Donepezil 10mg QDn=10 Participants	246	166.6

Secondary/registry result/low confidence

Panel B: Vz/F After Administration of 6mg of MK-1167

Time frame:Day 31: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 120, 240, 360 and 480 hours postdose

ratio, descriptive

Posted result

Group	Value (geometric_mean), Liter	Geometric coefficient of variation
Panel B: MK-1167 6mg QD + Donepezil 10mg QDn=8 Participants	169	19.7

Secondary/registry result/low confidence

Panel B: Day 23 to Day 1 Accumulation Ratio of AUC0-24 After Administration of 6mg of MK-1167

Time frame:Days 1, 23: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose

concentration, descriptive

Posted result

Group	Value (geometric_mean), Ratio	Reported bounds
Panel B: MK-1167 6mg QD + Donepezil 10mg QDn=8 Participants	8.95	-7.80 - 10.27

Secondary/registry result/low confidence

Panel B: Day 31 to Day 1 Accumulation Ratio of AUC0-24 After Administration of 6mg of MK-1167

Time frame:Days 1, 31: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose

concentration, descriptive

Posted result

Group	Value (geometric_mean), Ratio	Reported bounds
Panel B: MK-1167 6mg QD + Donepezil 10mg QDn=8 Participants	9.26	-8.08 - 10.62

Secondary/registry result/low confidence

Panel B: Day 23 to Day 1 Accumulation Ratio of C24 After Administration of 6mg of MK-1167

Time frame:Days 1, 23: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose

concentration, descriptive

Posted result

Group	Value (geometric_mean), Ratio	Reported bounds
Panel B: MK-1167 6mg QD + Donepezil 10mg QDn=8 Participants	7.94	-6.64 - 9.50

Secondary/registry result/low confidence

Panel B: Day 31 to Day 1 Accumulation Ratio of C24 After Administration of 6mg of MK-1167

Time frame:Days 1, 31: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose

concentration, descriptive

Posted result

Group	Value (geometric_mean), Ratio	Reported bounds
Panel B: MK-1167 6mg QD + Donepezil 10mg QDn=8 Participants	9.54	-7.97 - 11.40

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 21, 2026

Endpoint classificationDelfa ADRD endpoint taxonomy

Results tableClinicalTrials.gov results section

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.